Literature DB >> 24399630

Efficacy of lower-limb muscle training modalities in severely dyspnoeic individuals with COPD and quadriceps muscle weakness: results from the DICES trial.

Maurice J H Sillen1, Frits M E Franssen1, Jeannet M L Delbressine1, Anouk W Vaes1, Emiel F M Wouters2, Martijn A Spruit1.   

Abstract

RATIONALE: Strength training and neuromuscular electrical stimulation (NMES) improve lower-limb muscle function in dyspnoeic individuals with chronic obstructive pulmonary disease (COPD). However, high-frequency NMES (HF-NMES) and strength training have never been compared head-to-head; and effects of low-frequency NMES (LF-NMES) have never been studied in COPD. Therefore, the optimal training modality to improve lower-limb muscle function, exercise performance and other patient-related outcomes in individuals with severe COPD remains unknown.
OBJECTIVES: To study prospectively the efficacy of HF-NMES (75 Hz), LF-NMES (15 Hz) or strength training in severely dyspnoeic individuals with COPD with quadriceps muscle weakness at baseline.
METHODS: 120 individuals with COPD (FEV1: 33±1% predicted, men: 52%, age: 64.8±0.8 years) were randomised to HF-NMES, LF-NMES or strength training as part of a comprehensive inpatient pulmonary rehabilitation programme. No treadmill walking or stationary cycling was provided.
MEASUREMENTS AND MAIN RESULTS: Groups were comparable at baseline. Quadriceps muscle strength increased after HF-NMES (+10.8 Newton-metre (Nm)) or strength training (+6.1 Nm; both p<0.01), but not after LF-NMES (+1.4 Nm; p=0.43). Quadriceps muscle endurance, exercise performance, lower-limb fat-free mass, exercise-induced symptoms of dyspnoea and fatigue improved significantly compared with baseline after HF-NMES, LF-NMES or strength training. The increase in quadriceps muscle strength and muscle endurance was greater after HF-NMES than after LF-NMES.
CONCLUSIONS: HF-NMES is equally effective as strength training in severely dyspnoeic individuals with COPD and muscle weakness in strengthening the quadriceps muscles and thus may be a good alternative in this particular group of patients. HF-NMES, LF-NMES and strength training were effective in improving exercise performance in severely dyspnoeic individuals with COPD and quadriceps weakness. TRIAL REGISTRATION: NTR2322. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Entities:  

Keywords:  COPD Pathology; Exercise; Pulmonary Rehabilitation

Mesh:

Year:  2014        PMID: 24399630     DOI: 10.1136/thoraxjnl-2013-204388

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  22 in total

Review 1.  Clinical management of chronic obstructive pulmonary disease patients with muscle dysfunction.

Authors:  Joaquim Gea; Carme Casadevall; Sergi Pascual; Mauricio Orozco-Levi; Esther Barreiro
Journal:  J Thorac Dis       Date:  2016-11       Impact factor: 2.895

2.  Neuromuscular Electrical Stimulation for Treatment of Muscle Impairment: Critical Review and Recommendations for Clinical Practice.

Authors:  Ethne L Nussbaum; Pamela Houghton; Joseph Anthony; Sandy Rennie; Barbara L Shay; Alison M Hoens
Journal:  Physiother Can       Date:  2017       Impact factor: 1.037

3.  Beta-alanine supplementation in patients with COPD receiving non-linear periodised exercise training or neuromuscular electrical stimulation: protocol of two randomised, double-blind, placebo-controlled trials.

Authors:  Roy Meys; Anouk A F Stoffels; Jana de Brandt; Hieronymus W H van Hees; Frits M E Franssen; Maurice J H Sillen; Emiel F M Wouters; Chris Burtin; Peter Klijn; Eline Bij de Vaate; Bram van den Borst; Jacqueline M Otker; Jos Donkers; Florence N Schleich; Maurice Hayot; Pascal Pomiès; Inge Everaert; Wim Derave; Martijn A Spruit
Journal:  BMJ Open       Date:  2020-09-13       Impact factor: 2.692

4.  Neuromuscular electrical stimulation improves exercise capacity in adult patients with chronic lung disease: a meta-analysis of English studies.

Authors:  Haihong Gong; Qinghe Jiang; Dongchao Shen; Jinming Gao
Journal:  J Thorac Dis       Date:  2018-12       Impact factor: 2.895

Review 5.  Neuromuscular electrostimulation for adults with chronic obstructive pulmonary disease.

Authors:  Kylie Hill; Vinicius Cavalheri; Sunita Mathur; Marc Roig; Tania Janaudis-Ferreira; Priscila Robles; Thomas E Dolmage; Roger Goldstein
Journal:  Cochrane Database Syst Rev       Date:  2018-05-29

6.  Analysis of three different equations for predicting quadriceps femoris muscle strength in patients with COPD.

Authors:  Aline Gonçalves Nellessen; Leila Donária; Nidia Aparecida Hernandes; Fabio Pitta
Journal:  J Bras Pneumol       Date:  2015 Jul-Aug       Impact factor: 2.624

7.  Metabolic load during strength training or NMES in individuals with COPD: results from the DICES trial.

Authors:  Maurice J H Sillen; Frits M E Franssen; Anouk W Vaes; Jeannet M L Delbressine; Emiel F M Wouters; Martijn A Spruit
Journal:  BMC Pulm Med       Date:  2014-09-02       Impact factor: 3.317

Review 8.  Neuromuscular electrical stimulation for muscle weakness in adults with advanced disease.

Authors:  Sarah Jones; William D-C Man; Wei Gao; Irene J Higginson; Andrew Wilcock; Matthew Maddocks
Journal:  Cochrane Database Syst Rev       Date:  2016-10-17

9.  Comparison of oxygen uptake during cycle ergometry with and without functional electrical stimulation in patients with COPD: protocol for a randomised, single-blind, placebo-controlled, cross-over trial.

Authors:  Clément Medrinal; Guillaume Prieur; David Debeaumont; Aurora Robledo Quesada; Yann Combret; Jean Quieffin; Olivier Contal; Bouchra Lamia
Journal:  BMJ Open Respir Res       Date:  2016-04-12

10.  Electrical stimulation influences chronic intermittent hypoxia-hypercapnia induction of muscle fibre transformation by regulating the microRNA/Sox6 pathway.

Authors:  Shiyuan Huang; Lu Jin; Jie Shen; Ping Shang; Xianxun Jiang; Xiaotong Wang
Journal:  Sci Rep       Date:  2016-05-20       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.